Genmab A/S vs Perrigo Company plc: SG&A Expense Trends

SG&A Expense Trends: Genmab A/S vs Perrigo Company plc

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Genmab A/S and Perrigo Company plc from 2014 to 2023. Over this period, Genmab A/S has seen a staggering increase in SG&A expenses, growing by over 4,000%, from approximately $80 million in 2014 to nearly $3.3 billion in 2023. This reflects Genmab's aggressive expansion and investment in its operations.

Conversely, Perrigo Company plc's SG&A expenses have remained relatively stable, with a modest increase of about 89% over the same period, indicating a more conservative financial strategy. This contrast highlights the differing business models and growth strategies of these two pharmaceutical giants. As the industry continues to evolve, monitoring these financial metrics will be key to understanding future market dynamics.